
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11366617/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. Journal of Infectious Diseases, 2022, 225, 1741-1749.	4.0	35
2	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2022, , .	3.0	0
3	Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa. Aids, 2022, 36, 933-940.	2.2	15
4	Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 310-317.	2.1	1
5	Miniature mass spectrometer–based point-of-care assay for cabotegravir and rilpivirine in whole blood. Analytical and Bioanalytical Chemistry, 2022, 414, 3387-3395.	3.7	11
6	Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention. Polymers, 2022, 14, 1196.	4.5	3
7	Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 390-395.	2.1	1
8	Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet, The, 2022, 399, 1779-1789.	13.7	177
9	Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 251-260.	2.1	12
10	Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women. Aids, 2022, 36, 1151-1159.	2.2	8
11	The use of technology-based adherence monitoring in the treatment of hepatitis C virus. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612210956.	1.8	2
12	Usability and effectiveness of adherence monitoring of a mobile app designed to monitor and improve adherence to event-driven and daily HIV pre-exposure prophylaxis among men who have sex with men in Taiwan. Digital Health, 2022, 8, 205520762211027.	1.8	1
13	Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses, 2022, 38, 939-943.	1.1	4
14	PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. Journal of the International AIDS Society, 2022, 25, .	3.0	29
15	Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study. Clinical Infectious Diseases, 2021, 73, e2117-e2123.	5.8	33
16	Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa. Clinical Infectious Diseases, 2021, 73, e1893-e1900.	5.8	35
17	Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis. Clinical Infectious Diseases, 2021, 72, 2025-2028.	5.8	4
18	Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis. AIDS Research and Human Retroviruses, 2021, 37, 421-428.	1.1	12

#	Article	IF	CITATIONS
19	Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots. Pharmacotherapy, 2021, 41, 291-298.	2.6	1
20	Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 73-80.	2.1	6
21	Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. Lancet HIV,the, 2021, 8, e130-e137.	4.7	41
22	Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. Clinical Infectious Diseases, 2021, 73, 1149-1156.	5.8	15
23	A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis. AIDS Research and Human Retroviruses, 2021, 37, 529-533.	1.1	1
24	Lower Urine Tenofovir Concentrations Among Individuals Taking Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Implications for Point-of-Care Testing. Open Forum Infectious Diseases, 2021, 8, ofab200.	0.9	9
25	Improving adherence to daily preexposure prophylaxis among MSM in Amsterdam by providing feedback via a mobile application. Aids, 2021, 35, 1823-1834.	2.2	7
26	Adherence to eventâ€driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3â€monthly questionnaires and intracellular TFVâ€DP. Journal of the International AIDS Society, 2021, 24, e25708.	3.0	19
27	Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 671-679.	2.1	16
28	Using the adherenceâ€efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial. Journal of the International AIDS Society, 2021, 24, e25744.	3.0	12
29	A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 655-669.	1.8	1
30	PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial. PLoS Medicine, 2021, 18, e1003670.	8.4	87
31	Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence. Aids, 2021, 35, 1949-1956.	2.2	8
32	Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV preâ€exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial. Journal of the International AIDS Society, 2021, 24, e25731.	3.0	17
33	Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis. AIDS Research and Human Retroviruses, 2021, 37, 407-408.	1.1	1
34	The Magnetic Couples Study: protocol for a mixed methods prospective cohort study of HIV-serodifferent heterosexual couples' perspectives and use of pre-exposure prophylaxis (PrEP). BMJ Open, 2021, 11, e048993.	1.9	3
35	Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 2675-2680.	3.0	6
36	Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. Aids, 2021, 35, 2481-2487.	2.2	8

#	Article	IF	CITATIONS
37	Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV. Open Forum Infectious Diseases, 2021, 8, ofab463.	0.9	13
38	Beyond HIV viral load: application of pharmacologic measures to identify ART adherence mismatch. Therapeutic Advances in Infectious Disease, 2021, 8, 204993612110105.	1.8	4
39	Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIVâ€Challenged Nonhuman Primates. Advanced Therapeutics, 2021, 4, 2000163.	3.2	28
40	Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study. Open Forum Infectious Diseases, 2021, 8, ofaa564.	0.9	14
41	Associations Between Tenofovir Diphosphate in Dried Blood Spots, Impaired Physical Function, and Fracture Risk. Open Forum Infectious Diseases, 2021, 8, ofaa577.	0.9	2
42	Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to firstâ€line therapy in South Africa: a case–control cohort study. Journal of the International AIDS Society, 2021, 24, e25849.	3.0	5
43	Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. Clinical Infectious Diseases, 2020, 70, 687-691.	5.8	22
44	Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV. AIDS Research and Human Retroviruses, 2020, 36, 173-175.	1.1	4
45	Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for Onâ€Demand HIV Preexposure Prophylaxis. Clinical Pharmacology and Therapeutics, 2020, 107, 1200-1208.	4.7	3
46	Direct quantitation of tenofovir diphosphate in human blood with mass spectrometry for adherence monitoring. Analytical and Bioanalytical Chemistry, 2020, 412, 1243-1249.	3.7	17
47	Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2020, 7, ofaa391.	0.9	4
48	Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet, The, 2020, 396, 239-254.	13.7	245
49	HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study. AIDS Patient Care and STDs, 2020, 34, 295-302.	2.5	5
50	Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. Pharmaceutics, 2020, 12, 981.	4.5	13
51	Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. Journal of Antimicrobial Chemotherapy, 2020, 75, 3303-3310.	3.0	9
52	Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV. Journal of Antimicrobial Chemotherapy, 2020, 75, 1591-1598.	3.0	14
53	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 323-330.	2.1	26
54	Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion. International Journal of Infectious Diseases, 2020, 94, 41-43.	3.3	9

#	Article	IF	CITATIONS
55	Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. International Journal of Pharmaceutics, 2020, 587, 119623.	5.2	10
56	Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program. Clinical Infectious Diseases, 2020, 71, e509-e512.	5.8	13
57	Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 463-474.	3.3	23
58	Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions. Current HIV/AIDS Reports, 2020, 17, 301-314.	3.1	83
59	Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 483-488.	2.1	4
60	Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV. Frontiers in Pharmacology, 2020, 11, 1288.	3.5	0
61	Pharmacokinetic and Pharmacodynamic Properties of Metronidazole in Pediatric Patients With Acute Appendicitis: A Prospective Study. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 297-302.	1.3	9
62	Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections. Clinical Infectious Diseases, 2019, 68, 1335-1342.	5.8	61
63	Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial. Lancet HIV,the, 2019, 6, e498-e508.	4.7	35
64	Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study. PLoS ONE, 2019, 14, e0221281.	2.5	24
65	Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2019, 74, 1395-1401.	3.0	14
66	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS Research and Human Retroviruses, 2019, 35, 788-793.	1.1	8
67	Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. Journal of Antimicrobial Chemotherapy, 2019, 74, 2360-2364.	3.0	13
68	Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate. Journal of Antimicrobial Chemotherapy, 2019, 74, 2352-2359.	3.0	9
69	Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1228-1233.	1.2	17
70	Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy. AIDS and Behavior, 2019, 23, 3493-3502.	2.7	16
71	Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV. Journal of Infectious Diseases, 2019, 220, 635-642.	4.0	43
72	Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821988845.	1.5	17

#	Article	IF	CITATIONS
73	Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 158-162.	2.1	16
74	Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 166-174.	2.1	15
75	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. Aids, 2019, 33, 237-246.	2.2	17
76	Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking. Journal of NeuroVirology, 2019, 25, 324-330.	2.1	11
77	Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report. Lancet HIV,the, 2019, 6, e43-e50.	4.7	43
78	Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis. AIDS Research and Human Retroviruses, 2019, 35, 123-128.	1.1	7
79	Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study. Clinical Infectious Diseases, 2019, 68, 2010-2017.	5.8	96
80	Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048. Clinical Infectious Diseases, 2019, 68, 1129-1135.	5.8	14
81	Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings. Clinical Infectious Diseases, 2019, 68, 1136-1143.	5.8	22
82	Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV,the, 2018, 5, e136-e145.	4.7	130
83	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clinical Infectious Diseases, 2018, 67, 411-419.	5.8	50
84	Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study. Clinical Infectious Diseases, 2018, 66, 1712-1721.	5.8	48
85	Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States. Clinical Infectious Diseases, 2018, 66, 213-219.	5.8	82
86	Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV,the, 2018, 5, e68-e78.	4.7	96
87	Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 193-198.	2.1	35
88	Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 295-298.	2.1	23
89	Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	182
90	Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine. Aids, 2018, 32, 2189-2194.	2.2	14

#	Article	IF	CITATIONS
91	Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1. Emerging Infectious Diseases, 2018, 24, .	4.3	38
92	What Can Urine Tell Us About Medication Adherence?. EClinicalMedicine, 2018, 2-3, 5-6.	7.1	11
93	Pharmacologicâ€Based Methods of Adherence Assessment in <scp>HIV</scp> Prevention. Clinical Pharmacology and Therapeutics, 2018, 104, 1056-1059.	4.7	29
94	Cryopreservation of human mucosal tissues. PLoS ONE, 2018, 13, e0200653.	2.5	14
95	Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor. AIDS Research and Human Retroviruses, 2018, 34, 835-837.	1.1	12
96	In-capillary microextraction for direct mass spectrometry analysis of biological samples. Talanta, 2018, 189, 451-457.	5.5	15
97	Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. Journal of Antimicrobial Chemotherapy, 2018, 73, 2112-2119.	3.0	15
98	Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. Journal of Controlled Release, 2018, 286, 315-325.	9.9	66
99	Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	3
100	Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis. Aids, 2018, 32, 1891-1898.	2.2	31
101	Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial. PLoS ONE, 2018, 13, e0190118.	2.5	18
102	Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis. New England Journal of Medicine, 2017, 376, 501-502.	27.0	97
103	Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 271-279.	2.1	40
104	Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users. Aids, 2017, 31, 1709-1714.	2.2	103
105	Inflammation and pharmacokinetics: potential implications for HIV-infection. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 641-650.	3.3	24
106	Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 501-511.	2.1	60
107	Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. Aids, 2017, 31, 2245-2251.	2.2	47
108	Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e104-e106.	2.1	64

#	Article	IF	CITATIONS
109	Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Lancet HIV,the, 2017, 4, e522-e528.	4.7	69
110	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 177-182.	2.1	25
111	Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Clinical Infectious Diseases, 2017, 64, 317-325.	5.8	54
112	Development and validation of an LC–MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate. Biomedical Chromatography, 2017, 31, e3820.	1.7	5
113	Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial. Journal of Antimicrobial Chemotherapy, 2017, 72, 478-485.	3.0	37
114	A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells. Pharmaceutical Research, 2017, 34, 73-83.	3.5	22
115	High preâ€exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project. Journal of the International AIDS Society, 2017, 20, 21472.	3.0	98
116	Nondaily preexposure prophylaxis for HIV prevention. Current Opinion in HIV and AIDS, 2016, 11, 94-101.	3.8	36
117	A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring. Aids, 2016, 30, 743-751.	2.2	27
118	Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression. Hepatology, 2016, 64, 999-1000.	7.3	3
119	Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. Journal of Pharmaceutical and Biomedical Analysis, 2016, 122, 16-20.	2.8	100
120	Pharmacology supports on-demand PrEP. Lancet HIV,the, 2016, 3, e405-e406.	4.7	17
121	Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression. Clinical Infectious Diseases, 2016, 63, 1661-1667.	5.8	78
122	Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrobial Agents and Chemotherapy, 2016, 60, 5387-5392.	3.2	11
123	Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Research and Human Retroviruses, 2016, 32, 981-991.	1.1	66
124	Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrobial Agents and Chemotherapy, 2016, 60, 6692-6697.	3.2	59
125	Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, S230-S234.	2.1	17
126	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clinical Infectious Diseases, 2016, 62, 1172-1177.	5.8	40

#	Article	IF	CITATIONS
127	Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). Journal of Antimicrobial Chemotherapy, 2016, 71, 1609-1618.	3.0	11
128	Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services. JAMA Internal Medicine, 2016, 176, 75.	5.1	535
129	Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Research and Human Retroviruses, 2016, 32, 32-43.	1.1	148
130	Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting. Acta Diabetologica, 2016, 53, 331-333.	2.5	8
131	Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. PLoS ONE, 2016, 11, e0165505.	2.5	10
132	Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. AIDS Research and Human Retroviruses, 2015, 31, 1015-1022.	1.1	1
133	Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. Journal of Infectious Diseases, 2015, 212, 1988-1995.	4.0	26
134	Measurement of intracellular ribavirin mono-, di- and triphosphate using solid phase extraction and LC–MS/MS quantification. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 978-979, 163-172.	2.3	24
135	Population Pharmacokinetic Modeling of Plasma and Intracellular Ribavirin Concentrations in Patients with Chronic Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 2179-2188.	3.2	28
136	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2015, 61, 572-580.	5.8	132
137	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. Journal of Infectious Diseases, 2015, 212, 1402-1406.	4.0	62
138	Dose Response for Starting and Stopping HIV Preexposure Prophylaxis for Men Who Have Sex With Men. Clinical Infectious Diseases, 2015, 60, 804-810.	5.8	53
139	Reduced Immune Activation During Tenofovir–Emtricitabine Therapy in HIV-Negative Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 495-501.	2.1	19
140	Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 13-20.	2.1	72
141	Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells. Antimicrobial Agents and Chemotherapy, 2015, 59, 7671-7679.	3.2	30
142	Short Communication: Tenofovir Diphosphate in Dried Blood Spots As an Objective Measure of Adherence in HIV-Infected Women. AIDS Research and Human Retroviruses, 2015, 31, 428-432.	1.1	35
143	Strong Relationship between Oral Dose and Tenofovir Hair Levels in a Randomized Trial: Hair as a Potential Adherence Measure for Pre-Exposure Prophylaxis (PrEP). PLoS ONE, 2014, 9, e83736.	2.5	125
144	Patterns and Correlates of PrEP Drug Detection Among MSM and Transgender Women in the Global iPrEx Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 528-537.	2.1	63

#	Article	IF	CITATIONS
145	Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 530-537.	2.1	73
146	Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission. Journal of Antimicrobial Chemotherapy, 2014, 69, 2470-2476.	3.0	19
147	Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC–MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 144-151.	2.8	51
148	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infectious Diseases, The, 2014, 14, 820-829.	9.1	1,039
149	Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 944, 18-24.	2.3	25
150	Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its <i>R</i> â€isomer in human plasma. Biomedical Chromatography, 2014, 28, 1714-1721.	1.7	2
151	HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. Journal of Infectious Diseases, 2014, 210, 1217-1227.	4.0	68
152	Clinical pharmacokinetics of antiretroviral drugs in older persons . Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 573-588.	3.3	35
153	Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure. AIDS Research and Human Retroviruses, 2013, 29, 384-390.	1.1	257
154	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. Science Translational Medicine, 2012, 4, 151ra125.	12.4	807
155	Effect of HIV-1 Infection and Sex on the Cellular Pharmacology of the Antiretroviral Drugs Zidovudine and Lamivudine. Antimicrobial Agents and Chemotherapy, 2012, 56, 3011-3019.	3.2	12
156	Validation of a sensitive LC/MS/MS method for the determination of zidovudine and lamivudine in human plasma. Biomedical Chromatography, 2012, 26, 12-20.	1.7	18
157	A Population Pharmacokinetic-Pharmacogenetic Analysis of Atazanavir. AIDS Research and Human Retroviruses, 2012, 28, 1227-1234.	1.1	39
158	Review and management of drug interactions with boceprevir and telaprevir. Hepatology, 2012, 55, 1620-1628.	7.3	123
159	Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC–MS/MS detection. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 390-401.	2.8	97
160	Effect of Nucleoside and Nucleotide Analog Reverse Transcriptase Inhibitors on Cell-Mediated Immune Functions. AIDS Research and Human Retroviruses, 2011, 27, 47-55.	1.1	13
161	Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. Journal of Antimicrobial Chemotherapy, 2011, 66, 240-250.	3.0	159
162	Atazanavir Metabolism According to CYP3A5 Status: An In Vitro-In Vivo Assessment. Drug Metabolism and Disposition, 2011, 39, 522-527.	3.3	27

#	Article	IF	CITATIONS
163	Effect of Antacids on the Pharmacokinetics of Raltegravir in Human Immunodeficiency Virus-Seronegative Volunteers. Antimicrobial Agents and Chemotherapy, 2010, 54, 4999-5003.	3.2	49
164	Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine, 2010, 363, 2587-2599.	27.0	4,268
165	Zidovudine and Lamivudine for HIV Infection. Clinical Medicine Reviews in Therapeutics, 2010, 2, a2004.	0.2	15
166	Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. Journal of Antimicrobial Chemotherapy, 2009, 64, 1071-1079.	3.0	46
167	Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. Aids, 2009, 23, 1035-1046.	2.2	121
168	Cytokine and sex hormone effects on zidovudine- and lamivudine-triphosphate concentrations in vitro. Journal of Antimicrobial Chemotherapy, 2008, 62, 738-745.	3.0	9
169	Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 298-303.	2.1	143
170	Recent developments in the clinical pharmacology of anti-HIV nucleoside analogs. Current Opinion in HIV and AIDS, 2008, 3, 258-265.	3.8	8
171	Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. Aids, 2007, 21, 1849-1854.	2.2	27
172	Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 441-449.	2.1	146
173	Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography–tandem mass spectroscopy; an indirect quantitation methodology. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 831, 248-257.	2.3	42
174	Liquid chromatography–tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 843, 147-156.	2.3	71
175	Comment on: Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. Journal of Antimicrobial Chemotherapy, 2006, 58, 220-221.	3.0	6
176	Therapeutic drug monitoring: Pharmacologic considerations for antiretroviral drugs. Current HIV/AIDS Reports, 2005, 2, 61-67.	3.1	2
177	Stability of zidovudine with oxytocin in a simulated Y-site injection. American Journal of Health-System Pharmacy, 2004, 61, 394-396.	1.0	Ο
178	Reply to Stevens et al. Clinical Infectious Diseases, 2004, 39, 878-879.	5.8	4
179	The Cellular Pharmacology of Nucleoside―and Nucleotideâ€Analogue Reverseâ€Transcriptase Inhibitors and Its Relationship to Clinical Toxicities. Clinical Infectious Diseases, 2004, 38, 743-753.	5.8	127
180	Pharmacologic Perspectives for Once-Daily Antiretroviral Therapy. Annals of Pharmacotherapy, 2004, 38, 1924-1934.	1.9	14

#	Article	IF	CITATIONS
181	Updated clinical pharmacologic considerations for HIV-1 protease inhibitors. Current HIV/AIDS Reports, 2004, 1, 33-39.	3.1	4
182	CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. Aids, 2004, 18, 2442-4.	2.2	19
183	Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. Aids, 2003, 17, 2159-2168.	2.2	121
184	Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. Aids, 2002, 16, 551-560.	2.2	133
185	CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clinical Pharmacology and Therapeutics, 2002, 71, 280-285.	4.7	12
186	Clinical pharmacologic considerations for HIV-1 protease inhibitors. Current Infectious Disease Reports, 2001, 3, 381-387.	3.0	13
187	Pharmacological Basis for Concentration-Controlled Therapy with Zidovudine, Lamivudine, and Indinavir. Antimicrobial Agents and Chemotherapy, 2001, 45, 236-242.	3.2	62
188	Indinavir plasma protein binding in HIV-1-infected adults. Aids, 2000, 14, 2293-2297.	2.2	56
189	Zidovudine triphosphate and lamivudine triphosphate concentration–response relationships in HIV-infected persons. Aids, 2000, 14, 2137-2144.	2.2	103
190	Pharmacodynamics of Human Immunodeficiency Virus Type 1 Protease Inhibitors. Clinical Infectious Diseases, 2000, 30, S151-S159.	5.8	103
191	A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections. Drug Safety, 2000, 23, 131-142.	3.2	30
192	Cumulative tenofovir diphosphate exposure in persons with <scp>HIV</scp> taking single―vs. multipleâ€ŧablet regimens. Pharmacotherapy, 0, , .	2.6	1